	TOWNSEND			Denver, Color	ado	D-1- 41-
	and			Tel 303 571-4	000	Palo Alto
] 7	TOWNSEND			San Francisco Tel 416 576-02	, California 200	379 Lytton Avenue
and			Seattle, Washington		Second Floor Palo Alto	
	CREW			Tel 206 467-96 Walnut Creek		California 94301-1 Tel 650-326-2400
	LLP			Tel 925 472-50		Fax 650-326-2422
		FACS	IMILE COVER SH	HEET		
Date:			Client & Matter Nu		T	
October 08, 2002 To: Examiner Sharon Turner USPTO			15270J-004750US At Fax Number: 1-703-746-3141		No. Pages (including this one): 6 Confirmation Phone Number: 1-703-308-0056	
lessage ursuant	to your telephone roa		axing the Compu	Ricotion	For II	
e ssag e ⊔rsuant	ation No. 09/580,015		axing the Commu as previously faxe	nication ed on Oc	for the above- tober 7, 2002,	noted to fax number
lessage ursuant oplicatio 703-30	e: to your telephone roc		as providusty taxe	ed on Oc	tober 7, 2002,	to fax number
lessage ursuant oplicatio 703-30	e: to your telephone recon. Please note this C8-4242.	quest, we are re-ficommunication was	VERNIGHT COURIER	BE SE	NT BY MESSENGER	to fax number
lessage ursuant pplicatio 703-30	e: to your telephone recon. Please note this C8-4242.	Quest, we are re-ficommunication was	VERNIGHT COURIER	BE SE	NT BY MESSENGER	to fax number

OCT. 8. 2002 11:31AM

TTC PALO ALTO

NO. 0019 P. 2

* * * COMMUNICATION RESULT REPORT (OCT. 7.2002 9:05PM) * * *

FILE MODE OPTION ADDRESS (GROUP) TIL TOWNSEND&TOWNSEND

064 MEMORY TX ##41811#17033084242# OK P. 5/5

REASON FOR ERROR E-1) HANG UP OR LINE FAIL E-3) NO ANSWER

E-2) BUSY E-4) NO FACSIMILE CONNECTION

> Atty Docket No. 15270J-004750US Client Ref. No. 209-US-CII-8A

PTO FAX NO.:

1-703-308-4242

ATTENTION:

Examiner Sharon L. Turner

TELEPHONE NO.:

703-308-0056

Group Art Unit 1647

OFFICIAL COMMUNICATION

FOR THE PERSONAL ATTENTION OF

EXAMINER Sharon Turner

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents are being facsimile transmitted to the Patent and Trademark Office (Fax No.: 1-703-308-4242) for the Application of Dale B. Schenk, Application No. 09/580,015, filed May 26, 2000 for PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE on the date shown below.

Document Attached

Atty Docket No. 15270J-004750US Client Ref. No. 209-US-CIP8A

PTO FAX NO.;

1-703-308-4242

ATTENTION:

Examiner Sharon L. Turner

TELEPHONE NO.:

703-308-0056

Group Art Unit 1647

OFFICIAL COMMUNICATION

FOR THE PERSONAL ATTENTION OF

EXAMINER Sharon Turner

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents are being facsimile transmitted to the Patent and Trademark Office (Fax No.: 1-703-308-4242) for the Application of Dale B. Schenk, Application No. 09/580,015, filed May 26, 2000 for PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE on the date shown below.

Document Attached

1. Communication (4 pages).

Number of pages being transmitted, including this page: 5

Dated: October 7, 2002

Rosemarie L. Celli, Reg. No. 42,397

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (650) 326-2400

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834 Telephone: 650-326-2400

Fax: 650-326-2422

PA 3255695 vl

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office,

Fax No. 1-703-308-4242 on October 7, 2002.

Attorney Docket No.: 15270J-004750US

Client Ref. No.: 209-US-CIP8A

TOWNSEND and TOWNSEND and CREW A

Rosemarie L. Celli, Reg. No. 42,397

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Examiner:

Turner, Sharon

DALE B. SCHENK

Art Unit:

1647

Application No.: 09/580,015

COMMUNICATION

Filed: May 26, 2000

For: PREVENTION AND TREATMENT

OF AMYLOIDOGENIC DISEASE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

During a telephone conference with the undersigned attorney on October 3, 2002, the Examiner requested Applicant identify support in the priority applications for the above-captioned application for a method of preventing or treating an amyloidogenic disease in a patient, comprising administering to the patient an effective dosage of an antibody that binds to a component of an amyloid deposit in the patient. Applicant submits this paper in response to the Examiner's request.

The following priority claim has been made for the above-captioned application;

THIS APPLICATION IS A CIP OF	09/322,289	05/28/1999
AND THIS APPLICATION IS A CIP OF	09/201,430	11/30/1998
WHICH IS A NONPROVISIONAL OF	60/080,970	04/07/1998
	VV/V0U,5/U	U4/U7/199X

DALE B. SCHENK Application No.: 09/580,015

Page 2

<u>PATENT</u>

AND A NONPROVISIONAL OF AND THIS APPLICATION IS A CIP OF WHICH IS A NONPROVISIONAL OF AND IS A NONPROVISIONAL OF	60/067,740 PCT/US98/25386 60/080,970	12/02/1997 11/20/1998 04/07/1998
AND IS A NONPROVISIONAL OF	60/067,740	12/02/1997

Support for a method of preventing or treating an amyloidogenic disease in a patient, comprising administering to the patient an effective dosage of an antibody that binds to a component of an amyloid deposit in the patient is found throughout U.S. Application No. 09/322,289 filed May 28, 1999, e.g.,

```
page 2, line 24 to page 3, line 15; page 8, lines 11-26; page 14, line14 to page 23, line 14; page 28, line 11 to page 29, line 16; page 32, lines 13-17; Example V, page 57; Example VI, page 57 to page 58; Example XI, page 70 to page 79; Example XII, page 79 to page 80; and, claims 1-37 as originally filed.
```

Support for a method of preventing or treating an amyloidogenic disease in a patient, comprising administering to the patient an effective dosage of an antibody that binds to a component of an amyloid deposit in the patient is found throughout U.S. Application No. 09/201,430 filed November 30, 1998, e.g.,

```
page 3, lines 6-8;
page 4, lines 4-8;
page 5, lines 6-9;
page 11, line 27 to page 12, line 10;
page 13, lines 28-36;
page 17, line 37 to page 19, line 9;
page 24, lines 33-35;
```

PATENT

```
DALE B. SCHENK
Application No.: 09/580,015
Page 3

Example V, page 57;

Example VI, page 57 to page 58;

Example XI, page 72 to page 73; and,

claims 1, 8-15, 22, 24, 26-27, 42, and 49 as originally filed.
```

Support for a method of preventing or treating an amyloidogenic disease in a patient, comprising administering to the patient an effective dosage of an antibody that binds to a component of an amyloid deposit in the patient is found throughout U.S. Application No. 60/080,970 filed April 7, 1998, e.g.,

```
page 3, lines 31-35;
page 7, lines 23-30;
page 8, lines 4-7;
page 13, line 3 to page 14, line 5;
page 18, lines 28-31;
page 19, lines 26-28;
Example VI, page 32,
Example VII, pages 32-33;
Example VIII, pages 33-34; and,
claims 1-11, 21, 23-24, 29, and 39-40 as originally filed
```

Support for a method of preventing or treating an amyloidogenic disease in a patient, comprising administering to the patient an effective dosage of an antibody that binds to a component of an amyloid deposit in the patient is found throughout U.S. Application No. 60/067,740 filed December 2, 1997, e.g.,

```
page 3, line 35 to page 4, line 3;
page 4, lines 6-11;
page 6, line 32 to page 7, line 23;
page 9, lines 32-35; and,
claims 1-11, 12, 21, 23-24, and 28 as originally filed.
```

DALE B. SCHENK

Application No.: 09/580,015

Page 4

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted,

Rosemarie L. Cel Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834 Tel: 650-326-2400

Fax: 650-326-2422 RLC:rlc PA 3255463 v1